Posted on 4/9/19
3 Reasons Bristol-Myers Could Become One Of The Best Investments Of The Next 5 Years
SummaryNow that my retirement portfolio is recession ready, with zero margin and a total focus on blue-chip dividend stocks, I'm able to aggressively buy deep value . . .
Posted on 4/8/19
Horizon Technology Finance Provides $20 Million Venture Loan Facility to Encore Dermatology
Horizon Technology Finance Corporation (NASDAQ: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in . . .
Posted on 4/8/19
Pulmatrix Closes $16.6 Million Upsized Public Offering
Pulmatrix, Inc. (NASDAQ: PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554 common units and 8,947,112 pre-funded units at . . .
Posted on 4/8/19
T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical . . .
Posted on 4/8/19
Homology Medicines Announces Proposed Public Offering of Common Stock
BEDFORD, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced that it intends to offer and sell, . . .
Posted on 4/8/19
Here's Why Syros Pharmaceuticals Is Collapsing Today
What happenedShares of Syros Pharmaceuticals (NASDAQ:SYRS) fell more than 26% today after the development-stage company announced the pricing of a stock offering. The business will sell . . .
Posted on 4/8/19
Should Biogen Investors Be Extra Nervous Right Now?
It seems like Biogen (NASDAQ:BIIB) just can't catch a break. In March, the biotech giant's late-stage Alzheimer's disease program imploded and now the only product pushing . . .
Posted on 4/8/19
Why Abiomed Stock Fell 15% in March
What happenedAbiomed (NASDAQ:ABMD) stock dropped 14.6% in March, according to data from S&P Global Market Intelligence.Shares of the Massachusetts-based maker of minimally invasive heart pumps are . . .
Posted on 4/8/19
I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris
I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghaiwith an exclusive focus on the development of potential first-in-class and best-in-class biologics in immuno-oncology and . . .
Posted on 4/7/19
Syros Prices $70M Concurrent Public Offerings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its . . .
Posted on 4/5/19
Why Biogen Stock Tanked in March
What happenedShares of Biogen (NASDAQ:BIIB) shed 29.2% of their value last month, according to data from S&P Global Market Intelligence. What went wrong for the biotech?Biogen . . .
Posted on 4/5/19
1 Biotech That Biogen Should Buy ... but Probably Won't
Biogen's (NASDAQ:BIIB) disclosure that aducanumab doesn't appear to help patients with Alzheimer's disease is a major blow to the big biotech's future growth, especially since its . . .
Posted on 4/5/19
AquaBounty Technologies Prices of $5.75M Public Offering of Common Stock
MAYNARD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (Nasdaq: AQB), a biotechnology company focused on enhancing productivity in the aquaculture market and a . . .
Posted on 4/5/19
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, . . .
Posted on 4/5/19
Syros Announces Proposed Concurrent Public Offerings of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to . . .
Posted on 4/5/19
Catapult and Smithwise To Merge
Two medical device development firms, Catapult Product Development, Inc. and Smithwise, Inc. announced today they have agreed to a merger
Posted on 4/4/19
Pulmatrix Prices $14.4 Million Upsized Public Offering
Pulmatrix, Inc. (NASDAQ: PULM) today announced the pricing of its previously announced underwritten public offering of an aggregate of 10,666,666 units at a price to the public . . .
Posted on 4/3/19
AVEO Pharmaceuticals Announces Proposed Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, . . .
Posted on 4/3/19
Aileron Therapeutics Completes $26M Private Placement
Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter Management, joins Aileron’s Board of DirectorsWATERTOWN, Mass., April 03, 2019 (GLOBE NEWSWIRE) . . .
Posted on 4/3/19
Chiasma Closes $34.5M Offering of Common Stock
WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and . . .
Posted on 4/3/19
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and BlueRock Therapeutics, LP, a leading engineered cell . . .
Posted on 4/3/19
Blueprint Medicines Announces Closing of Public Offering
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the closing of its previously . . .
Posted on 4/2/19
Fusion Pharmaceuticals Raises $105 Million in Oversubscribed Series B Financing
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer,
Posted on 4/2/19
Lantheus Enters Strategic Collaboration with Cerevast
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc., a global leader in the development, manufacture and commercialization of innovative . . .
Posted on 4/2/19
What's Wrong With Sarepta Therapeutics?
SummaryUnexpected gene therapy update was mostly reiterating what investors already knew.Biogen's buyback tossed some cold water on Sarepta buyout speculation.Selloff after $350 million public offering is . . .

